


## Lappaconitine Hydrobromide Datasheet

5<sup>th</sup> Edition (Revised in January, 2017)**[ Product Information ]****Name:** Lappaconitine Hydrobromide**Catalog No.:** CFN90361**Cas No.:** 97792-45-5**Purity:** >=98%**M.F:** C<sub>32</sub>H<sub>44</sub>N<sub>2</sub>O<sub>8</sub>.HBr**M.W:** 665.61**Physical Description:** Powder**Synonyms:** (1a,14a,16b)-20-Ethyl-1,14,16-trimethoxyaconitane-4,8,9-triol-4-(2-(acetylamino)benzoate) hydrobromide; Lappaconite HBr.**[ Intended Use ]**

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

**[ Source ]**The roots of *Aconitum carmichaeli* Debx.**[ Biological Activity or Inhibitors ]**

Fos protein expression in dorsal horn of spinal cord and pain reaction can be suppressed by intraperitoneal injection of lappaconitine in a dose-dependent manner in rats, lappaconitine hydrobromide may reinforce the activity of pain modulation system in brainstem and inhibit the inputs of peripheral pain message through enhancing norepinephrine releasing.<sup>[1]</sup>

Lappaconitine hydrobromide can remove inflammation and swelling, lower temperature and relieve heat, it also can be used for local anesthesia.<sup>[2]</sup>

Lappaconitine hydrobromide injection and shenfu Injection have biphasic effect on inducing differentiation and apoptosis of HL-60, and this will supply the experimental evidence for warming-yang method in treating leukemia.<sup>[3]</sup>

The clathrate with hydrobromide of lappaconitine (I•HBr-IV) has a high activity on the two models of arrhythmia.<sup>[4]</sup>

## **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

## **[ HPLC Method ]<sup>[5]</sup>**

Mobile phase: 0.05 M NaH<sub>2</sub>PO<sub>4</sub>-Methanol=28:72;

Flow rate:1.0 ml/min;

Column temperature: 25°C;

The wave length of determination:252 nm.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

[1] Lin M, Lin C, Yang X. *Shanghai Medical Journal*, 2012, 87(3):1072-81.

[2] Yu J Z, Zhang B J, Jiang X T. *Academic Journal of Second Military Medical University*,

2005,26 (7) :822-4.

[3] Takagi T, Naito Y, Kajikawa H, *et al.* *Journal of Guangzhou University of Traditional Chinese Medicine*, 2008,134(4):385-90.

[4] Tolstikova T G, Bryzgalov A O, Sorokina I V, *et al.* *Letters in Drug Design & Discovery*, 2009, 6(7):475-7.

[5] Hu X L, Lei J, Wang F, *et al.* *China Pharmaceuticals*, 2012,21(16):29-31.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)